TetraLogic Pharmaceuticals (TLOG) Stock Price, News & Analysis

Company Overview

TetraLogic Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel immunotherapies and small-molecule therapeutics for the treatment of cancer and infectious diseases. Its primary focus is on synthetic carbohydrate-based vaccines that stimulate targeted immune responses against tumor-associated antigens, complemented by a small-molecule antibiotic platform designed to combat drug-resistant bacterial pathogens.

The company’s lead immunotherapy candidate, which targets mucin-based tumor antigens, is under evaluation in early-phase clinical trials in collaboration with academic research centers, with particular emphasis on breast and ovarian cancer indications. In parallel, TetraLogic advances a pipeline of preclinical small-molecule compounds engineered to disrupt essential bacterial survival mechanisms, addressing growing antibiotic resistance.

Headquartered in Bothell, Washington, TetraLogic was founded in the mid-2000s and leverages partnerships with research institutions to support discovery and development. The management team draws on extensive experience in oncology drug development and infectious disease research to guide the company’s strategic growth.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 25 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 5/30/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:TLOG
• Previous Symbol: NASDAQ:TLOG
• CIK: 1361248
• Web: www.tetralogicpharma.com
• Phone: (610) 889-9900
• Fax: 610-889-9994
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: 4.78